JP2023526469A5 - - Google Patents
Info
- Publication number
- JP2023526469A5 JP2023526469A5 JP2022570668A JP2022570668A JP2023526469A5 JP 2023526469 A5 JP2023526469 A5 JP 2023526469A5 JP 2022570668 A JP2022570668 A JP 2022570668A JP 2022570668 A JP2022570668 A JP 2022570668A JP 2023526469 A5 JP2023526469 A5 JP 2023526469A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide sequence
- variable domain
- chain variable
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063027935P | 2020-05-20 | 2020-05-20 | |
| US63/027,935 | 2020-05-20 | ||
| US202063032518P | 2020-05-29 | 2020-05-29 | |
| US63/032,518 | 2020-05-29 | ||
| US202063039977P | 2020-06-16 | 2020-06-16 | |
| US63/039,977 | 2020-06-16 | ||
| US202063060116P | 2020-08-02 | 2020-08-02 | |
| US63/060,116 | 2020-08-02 | ||
| US202063063106P | 2020-08-07 | 2020-08-07 | |
| US63/063,106 | 2020-08-07 | ||
| US202063117908P | 2020-11-24 | 2020-11-24 | |
| US63/117,908 | 2020-11-24 | ||
| US202063123767P | 2020-12-10 | 2020-12-10 | |
| US63/123,767 | 2020-12-10 | ||
| US202163165729P | 2021-03-24 | 2021-03-24 | |
| US63/165,729 | 2021-03-24 | ||
| PCT/US2021/033512 WO2021236997A2 (en) | 2020-05-20 | 2021-05-20 | Potent neutralizing antibodies against sars-cov-2, generation and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526469A JP2023526469A (ja) | 2023-06-21 |
| JP2023526469A5 true JP2023526469A5 (https=) | 2024-05-27 |
Family
ID=78707603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022570668A Pending JP2023526469A (ja) | 2020-05-20 | 2021-05-20 | ＳＡＲＳ－ＣｏＶ－２に対する強力な中和抗体、その生成および使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20230203134A1 (https=) |
| EP (1) | EP4153625A4 (https=) |
| JP (1) | JP2023526469A (https=) |
| KR (1) | KR20230024904A (https=) |
| AU (1) | AU2021277373A1 (https=) |
| BR (1) | BR112022023467A2 (https=) |
| CA (1) | CA3184184A1 (https=) |
| CL (1) | CL2022003215A1 (https=) |
| CO (1) | CO2022018192A2 (https=) |
| IL (1) | IL298263A (https=) |
| MX (1) | MX2022014420A (https=) |
| PH (1) | PH12022500025A1 (https=) |
| WO (4) | WO2021236997A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20240182T1 (hr) | 2020-03-26 | 2024-04-26 | Vanderbilt University | Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2) |
| EP4153625A4 (en) * | 2020-05-20 | 2024-09-25 | The Trustees Of Columbia University In The City Of New York | STRONG NEUTRALISING ANTIBODIES AGAINST SARS-COV-2, THEIR PRODUCTION AND USE |
| WO2024089277A2 (en) * | 2022-10-27 | 2024-05-02 | Oxford University Innovation Limited | Antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1778283A2 (en) * | 2004-06-30 | 2007-05-02 | ID Biomedical Corporation of Quebec | Vaccine compositions for treating coronavirus infection |
| WO2006124269A2 (en) * | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| CA2662350A1 (en) * | 2006-09-05 | 2008-03-13 | Medarex, Inc. | Antibodies to bone morphogenic proteins and receptors therefor and methods for their use |
| US7982016B2 (en) * | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| EP2242768A4 (en) * | 2008-01-17 | 2012-03-14 | Humabs Llc | CROSS-NEUTRALIZATION OF HUMAN MONOCLONAL ANTIBODIES AGAINST SARS-COV AND METHODS FOR THEIR APPLICATION |
| CN108610416B (zh) * | 2008-10-13 | 2022-01-14 | 生物医学研究所 | 登革热病毒中和抗体及其用途 |
| CA2742969A1 (en) * | 2008-11-07 | 2010-05-14 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
| CA2932405A1 (en) * | 2013-12-02 | 2015-06-11 | Aaron Diamond Aids Research Center | Improved hiv-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture |
| WO2016138160A1 (en) * | 2015-02-24 | 2016-09-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
| WO2016187220A2 (en) * | 2015-05-18 | 2016-11-24 | Five Prime Therapeutics, Inc. | Anti-ror1 antibodies |
| EP3356415B1 (en) * | 2015-09-29 | 2024-05-01 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
| CR20180365A (es) * | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| TWI848953B (zh) * | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| CN113056483B (zh) * | 2018-07-09 | 2025-08-01 | 戊瑞治疗有限公司 | 结合到ilt4的抗体 |
| EP4153625A4 (en) * | 2020-05-20 | 2024-09-25 | The Trustees Of Columbia University In The City Of New York | STRONG NEUTRALISING ANTIBODIES AGAINST SARS-COV-2, THEIR PRODUCTION AND USE |
-
2021
- 2021-05-20 EP EP21807600.8A patent/EP4153625A4/en not_active Withdrawn
- 2021-05-20 IL IL298263A patent/IL298263A/en unknown
- 2021-05-20 WO PCT/US2021/033512 patent/WO2021236997A2/en not_active Ceased
- 2021-05-20 AU AU2021277373A patent/AU2021277373A1/en not_active Abandoned
- 2021-05-20 BR BR112022023467A patent/BR112022023467A2/pt unknown
- 2021-05-20 MX MX2022014420A patent/MX2022014420A/es unknown
- 2021-05-20 US US17/999,387 patent/US20230203134A1/en active Pending
- 2021-05-20 WO PCT/US2021/033513 patent/WO2021236998A2/en not_active Ceased
- 2021-05-20 WO PCT/US2021/033511 patent/WO2021236996A2/en not_active Ceased
- 2021-05-20 US US17/999,544 patent/US20230203138A1/en active Pending
- 2021-05-20 KR KR1020227044068A patent/KR20230024904A/ko active Pending
- 2021-05-20 WO PCT/US2021/033510 patent/WO2021236995A2/en not_active Ceased
- 2021-05-20 US US17/999,391 patent/US20240002476A1/en active Pending
- 2021-05-20 PH PH1/2022/500025A patent/PH12022500025A1/en unknown
- 2021-05-20 CA CA3184184A patent/CA3184184A1/en active Pending
- 2021-05-20 JP JP2022570668A patent/JP2023526469A/ja active Pending
-
2022
- 2022-11-17 CL CL2022003215A patent/CL2022003215A1/es unknown
- 2022-12-15 CO CONC2022/0018192A patent/CO2022018192A2/es unknown